The information on this page was last updated on 31 March 2020.
As at 31 March 2020, the number of shares in issue was 59,416,134.
|Shareholder||Number||Ordinary Shares %|
|Icahn School of Medicine at Mount Sinai||8,853,426||14.90%|
|Lombard Odier & Co Ltd||2,869,334||4.83%|
|EKF Diagnostics Holdings Plc||2,677,981||4.51%|
|Canaccord Genuity Wealth Management||2,487,965||4.19%|
|Polar Capital, LLP||1,949,664||3.28%|
|O. James Sterling||1,902,640||3.20%|
|Legal & General Investment Management||1,805,283||3.04%|
|Director||Number||Ordinary Shares %|
Shares not in public hands
As at 31 March 2020 the percentage of AIM securities not in public hands was 55.53%. The securities not in public hands include all significant shareholders, the directors and senior management who are classed as persons discharging managerial responsibilities. There are no shares held in treasury.
Rights of shareholders
The rights of shareholders are governed by UK law.
Restrictions in transfer of ordinary shares
There are no restrictions on the transfer of the company’s ordinary shares.
UK City Code on Takeover and Mergers
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Other exchanges and trading platforms
All of the Company's shares are traded on AIM, a market of London Stock Exchange plc, and American Depositary Shares representing the Company’s ordinary shares are listed on the Nasdaq Global Market. The Company's shares are not traded on any other exchange or trading platform.
The Company is subject to the UK City Code on Takeovers and Mergers.